{"id":"W2586170806","doi":"10.1093/annonc/mdw373.08","title":"Interim analysis of a phase I dose escalation trial of the antibody drug conjugate (ADC) AGS15E (ASG-15ME) in patients (Pts) with metastatic urothelial cancer (mUC)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"ca_institutions":"Juravinski Cancer Centre; Sunnybrook Health Science Centre; BC Cancer Agency","funders":"Amgen","keywords":"Medicine; Internal medicine; Adverse effect; Interim analysis; Response Evaluation Criteria in Solid Tumors; Cancer; Gastroenterology; Phases of clinical research; Chemotherapy; Surgery; Urology; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003864667,0.001464069,0.002562657,0.0003134138,0.000482252,0.001491172,0.0006707321,0.001220145,0.005051198],"category_scores_gemma":[0.003131635,0.0005108567,0.003148438,0.0004539958,0.0007413484,0.001182102,0.000488748,0.003438926,0.0009557473],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008492206,"about_ca_system_score_gemma":0.00128558,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000508228,"about_ca_topic_score_gemma":0.001141103,"domain_scores_codex":[0.9987426,0.000624504,0.00006055576,0.0001882275,0.00009419397,0.0002898362],"domain_scores_gemma":[0.9980788,0.0006081924,0.0004136653,0.0003117195,0.0001118799,0.0004757754],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9328239,0.006746049,0.006562027,0.0003160005,0.002606003,0.0001659646,0.0001382913,0.004747978,0.00568938,0.0003351469,0.004124192,0.03574503],"study_design_scores_gemma":[0.4546309,0.4726733,0.04805645,0.00007398547,0.004300465,0.0004226239,0.0001582651,0.006444985,0.004702516,0.001839601,0.006621275,0.00007562594],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9857661,0.0022093,0.001717548,0.0008270831,0.0003471724,0.001649337,0.00348578,0.0001650227,0.003832634],"genre_scores_gemma":[0.9864836,0.0006248893,0.001811727,0.001071334,0.0001421929,0.001688925,0.004548588,0.0000525988,0.003576134],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005051198,"threshold_uncertainty_score":0.02043855,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06243164239010057,"score_gpt":0.4239651933169824,"score_spread":0.3615335509268818,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}